Cabezón, M., Arenillas Rocha, L., Zamora, L., & Group, C. (2021). Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Citação norma ChicagoCabezón, Marta, Leonor Arenillas Rocha, Lurdes Zamora, y CETLAM Group. Different Methylation Signatures At Diagnosis in Patients With High-risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Predict Azacitidine Response and Longer Survival. 2021.
Citação norma MLACabezón, Marta, Leonor Arenillas Rocha, Lurdes Zamora, y CETLAM Group. Different Methylation Signatures At Diagnosis in Patients With High-risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Predict Azacitidine Response and Longer Survival. 2021.